Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1) in the ATEMPT trial and the favorable toxicity profile associated with this agent make T-DM1 a potential therapeutic option for select patients with stage I HER2-positive breast cancer. Moreover, T-DM1 is an...

Descripción completa

Detalles Bibliográficos
Autores principales: Barroso-Sousa, Romualdo, Tarantino, Paolo, Tayob, Nabihah, Dang, Chau, Yardley, Denise A., Isakoff, Steven J., Valero, Vicente, Faggen, Meredith, Mulvey, Therese, Bose, Ron, Hu, Jiani, Weckstein, Douglas, Wolff, Antonio C., Reeder-Hayes, Katherine, Rugo, Hope S., Ramaswamy, Bhuvaneswari, Zuckerman, Dan, Hart, Lowell, Gadi, Vijayakrishna K., Constantine, Michael, Cheng, Kit, Briccetti, Frederick, Schneider, Bryan, Garrett, Audrey Merrill, Marcom, Kelly, Albain, Kathy, DeFusco, Patricia, Tung, Nadine, Ardman, Blair, Nanda, Rita, Jankowitz, Rachel C., Rimawi, Mothaffar, Abramson, Vandana, Pohlmann, Paula R., Van Poznak, Catherine, Forero-Torres, Andres, Liu, Minetta, Ruddy, Kathryn J., Zheng, Yue, Rosenberg, Shoshana M., Gelber, Richard D., Trippa, Lorenzo, Barry, William, DeMeo, Michelle, Burstein, Harold, Partridge, Ann, Winer, Eric P., Krop, Ian, Tolaney, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850608/
https://www.ncbi.nlm.nih.gov/pubmed/35173164
http://dx.doi.org/10.1038/s41523-022-00385-2

Ejemplares similares

Ejemplares similares